Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly.
Eur J Endocrinol
; 182(6): D17-D29, 2020 Jun.
Article
in En
| MEDLINE
| ID: mdl-32234975
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acromegaly
/
Receptors, Somatotropin
/
Human Growth Hormone
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Eur J Endocrinol
Journal subject:
ENDOCRINOLOGIA
Year:
2020
Type:
Article
Affiliation country:
Netherlands